Prescribing practices for intravenous aminoglycosides in UK Cystic Fibrosis clinics: A questionnaire survey  by Smyth, Alan R. & Campbell, Emma L.
Short Communicationwww.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 13 (2014) 424–427Prescribing practices for intravenous aminoglycosides in UK
Cystic Fibrosis clinics: A questionnaire surveyAlan R. Smyth ⁎, Emma L. Campbell
Division of Child Health, Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK
Received 2 August 2013; received in revised form 15 November 2013; accepted 18 November 2013
Available online 11 December 2013Abstract
Background: Intravenous aminoglycoside antibiotics are widely used to treat pulmonary infection with Pseudomonas aeruginosa in individuals
with cystic ﬁbrosis (CF). Over the last decade evidence has accumulated showing that the choice of aminoglycoside and the dosing regimen may
help reduce adverse effects such as nephrotoxicity.
Methods: We undertook an online survey to determine current practice in UK CF Centres.
Results: We received a response from 35/48 (73%) centres. A once daily regimen was used in 30/35 (86%) centres. Around one third had stopped
using gentamicin in the last 10 years. In most cases respondents reported changing practice in response to new evidence or evidence based
guidelines. Obstacles to introducing evidence based practice were identiﬁed both at the level of the CF Centre and the hospital trust.
Conclusions: A once daily aminoglycoside regimen is now used in the majority of UK CF Centres. Tobramycin is ﬁrst line and many centres have
stopped using gentamicin. Obstacles to evidence based practice remain in a minority of centres.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Aminoglycosides; Nephrotoxicity; Once daily dosing; Obstacles to evidence based practice1. Introduction
Aminoglycoside antibiotics are widely used for the man-
agement of pulmonary exacerbations in cystic fibrosis (CF) due
to Pseudomonas aeruginosa. In the UK around one third of CF
patients receive intravenous antibiotics in a year, for a median
of 23 days [1]. Aminoglycosides are recommended as first line
therapy [2] and so CF patients are vulnerable to adverse effects,
such as nephrotoxicity. The risk of acute kidney injury (AKI) is
greater in CF than in the general population (100 times greater
in children) and most episodes are related to aminoglycosides
[3]. There are a limited number of antibiotics which are active
against P. aeruginosa and so clinicians will continue to use
intravenous aminoglycosides. However there is good evidence
that nephrotoxicity may be reduced by using a once daily⁎ Corresponding author. Tel.: +44 115 823 0612; fax: +44 115 823 0626.
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http://dx.doi.org/10.1016/j.jcf.2013.11.007regimen [4] and by avoiding the use of gentamicin [3]. This
evidence has informed recommendations in treatment guide-
lines both in the UK [2] and in the US [5]. Indeed the guideline
recommendation on aminoglycoside use has been highlighted as
one of the few which is evidence based [5]. We therefore chose to
evaluate adherence to this recommendation as an example of
guideline adherence in CF. A decade ago, we conducted a survey
of aminoglycoside prescribing practices in UK CF centres which
showed low uptake of these strategies [6]. We wanted to know
whether practice has changed in the light of evidence from recent
research and so we repeated this survey.
2. Methods
We contacted the Centre Director for all UK CF centres by
email (using a contact list provided by the UK Cystic Fibrosis
Trust) and invited them to complete an online questionnaire
(Fig. 1) which asked about aminoglycoside prescribing practices
in their centre. Answers could be yes/no; choose one option;
choose one or more options; or free text, depending on theby Elsevier B.V. All rights reserved.
Fig. 1. Online questionnaire.
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2013 and a follow up to non-responders was sent a month later.
The online tool captured the email address of the respondent and
so duplicate responses from the same centre could be identified.
Where there was more than one response from the same centre,
we used the first response only. The questionnaire (Q1-3) asked
specifically about first line antibiotic therapy for P. aeruginosa
(the commonest indication for aminoglycosides in CF). This was to
avoid confusion with aminoglycosides given for other indications
such as intravenous amikacin for infection with Mycobacterium
abscessus, where a twice or three times daily regimen is
recommended [2].3. Results
We received a response from 35/48 (73%) centres, of which
21/35 (60%) were paediatric and 14/35 (40%) were adult.
Replies came from centres in England, Scotland, Wales and
Northern Ireland. All centres reported using an aminoglycoside
as part of an intravenous antibiotic regimen for infection with
P. aeruginosa (Q1) and all named tobramycin as their first line
aminoglycoside (Q2).
Results for Q3–Q9 by paediatric and adult centre separately
are given in Table 1. A once daily aminoglycoside regimen was
used by 30/35 (86%) centres; twice daily by 1/35 (3%), and
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they had changed the dosing regimen for aminoglycosides in
the last 10 years (Q4). Of these, 21 centres had changed from a
three times daily regimen to once daily, and one centre had
changed from three times daily to a twice daily regimen (Q5).
When asked the reason for changing (Q6), 19 respondents cited
the TOPIC study [7], 5 respondents the UK CF Trust Antibiotic
Guidelines [2] and 2 gave other reasons (such as local laboratory
data).
When asked if the specific aminoglycoside drug prescribed in
the centre had changed in the last 10 years (Q7), 10/35 (29%)
centres said they had made a change and 24/35 (69%) had not
(one did not reply to this question). Of the 10 centres who had
changed the antibiotic used, all had stopped using gentamicin
(Q8). The CF Trust Antibiotic Guidelines [2] were cited by 5
centres as a reason for changing; the UK case control study of
acute kidney injury [3] by 3 centres and 2 gave other reasons (Q9).
We received 11 free text responses (9 from paediatric centres)
to Q10 “If you have tried to change your aminoglycoside or
regimen, but have encountered difficulties, please describe these
briefly in the box”. Many of these were informative, raising
issues which fell into the following themes (direct quotations
from respondents have been used to illustrate these themes).
Some respondents gave more than one reason.• Training issues (3 respondents). “Lots of delays when
changing from TDS to OD Tobramycin due the training of
nurses and parents…”
• Difficulty arranging infusions (3 respondents). A once daily
aminoglycoside dose is administered by infusion (usually over
30 min) whereas three times daily doses may be given by
bolus. “Problems with od antibiotics infusion in the commu-
nity setting.”
• Laboratory unwilling to provide tobramycin assay for moni-
toring plasma levels (4 respondents). “Lab will only run a
gentamicin and not a tobramycin assay. They have agreed to
send away tobra levels”Table 1
Responses to questionnaire, presented by paediatric and adult centres. All centres respo
For free text responses to Q10 see results section (only two responses received from ad
Responses received (% of total responses)
Q3. Number using once daily regimen (%)
Q4. Change in dosing frequency in last 10y
Q5. How has it changed?
Q6. What has brought about this change? (Some gave more than one reason)
Q7 & Q8. Has your centre changed which aminoglycoside is prescribed & how
changed?
Number stopped using gentamicin in last 10y (%)
Q9. What has brought about this change?• Once daily prescribing for CF patients would be out of line
with policies for other patients increasing the risk of a drug
error (1 respondent). “Hospital policy for other aminogly-
cosides is 8 hourly—we discussed TOPIC findings several
times but we felt that clinical risk of Tobra overdose to CF
patients (receiving once daily) on same ward as medical
patients (receiving TDS aminoglycosides) would be too great.”4. Discussion
We have shown a profound change in aminoglycoside
prescribing practices, in UK CF Centres, over the last decade. At
the time of our previous survey [6] a once daily aminoglycoside
dosing regimen was used in 17% of UK CF Centres. Once daily
dosing is now used in 86% of centres. The use of tobramycin has
increased from 87% in our previous survey to its use in all centres
currently. Just under one third of centres responding had stopped
using gentamicin in the last 10 years. Appropriately, most
respondents cite high quality evidence or evidence based
guidelines as their reason for changing practice. Obstacles to
implementing evidence based practice include practical issues
(such as the need for an infusion device and training). However
the need for hospital wide change (in the assay performed and in
the use of once daily regimens in other patients) was a significant
obstacle in some centres. This is disappointing, as the evidence
suggests that a once daily regimen should be widely used amongst
all patients receiving aminoglycosides (not just those with CF)—
with few contraindications [8].
Our findings are in line with reported changes in practice in
Australia which have shown an increase in once daily dosing from
54% in 1999 [9] to 88% in 2009 [10]. There are no recent surveys
from the US, but once daily aminoglycoside dosing is now
recommended in US CF Foundation Guidelines for managing
pulmonary exacerbations [5].
Whilst our response rate was good (73% centres), 13 centres
did not respond and it is possible that there was a systematic bias in
the non-responders (such as centres not following evidence basednding used an aminoglycoside and all reported tobramycin as first line. (Q1 & Q2.)
ult centres).
Paediatric Adult
21 (60%) 14 (40%)
19 (90%) 11 (79%)
12 (57%) 10 (71%)
All reported change to once daily apart from one
centre (adult) which changed to twice daily.
TOPIC trial
Guidelines 4
TOPIC trial
Guidelines 1
Local data 2
has it
All centres, reporting a change, had stopped using
gentamicin.
6 (29%) 4 (29%)
Guidelines 3
Case control 2
Guidelines 2
Case control
1
Local data 2
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are informative but are limited by the study design (an online
questionnaire). Further valuable data, regarding obstacles to
implementing evidence based practice, could be obtained from
semi-structured interviews with key decision makers in UK CF
Centres and their hospital trusts.
In the setting of a clinical trial, once daily aminoglycoside
dosing for pulmonary exacerbations of CF results in less
nephrotoxicity [7]. Whether the widespread adoption of a safer
regimen in the UK will result in fewer cases of acute kidney
injury amongst CF patients is not known. However, data on
acute kidney injury, requiring dialysis, are recorded in the UK
CF Registry, allowing trends to be monitored. Therefore it may
become clear over the coming years if morbidity has been
reduced in this vulnerable group of patients.Conflict of interest statement
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